Biogen Aktie
| 201,04USD | 16,21USD | 8,77% |
WKN: 789617 / ISIN: US09062X1037
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 9 610 | 8 725 | 7 570 | 7 605 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 1,08 | 1,08 | 1,24 | 1,22 | 0,00 |
Bilanz (in Mio. USD) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 7 857 | 9 791 | 6 859 | 7 457 | 8 974 |
| Summe Anlagevermögen | 16 021 | 14 763 | 19 986 | 20 593 | 20 465 |
| Summe Aktiva | 23 877 | 24 554 | 26 845 | 28 049 | 29 440 |
Bilanz (in Mio. USD) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 12 918 | 11 166 | 12 045 | 11 333 | 11 183 |
| Summe Eigenkapital | 10 960 | 13 388 | 14 799 | 16 716 | 18 257 |
| Summe Passiva | 23 877 | 24 554 | 26 845 | 28 049 | 29 440 |
Adresse
| 225 Binney Street, 02142 Cambridge | |
| Telefon | +1 (617) 679-2000 |
| Internet | http://www.biogen.com |
Management
|
Adam Feire
Head-Business Development & External Innovation |
|
Adam Keeney
Executive VP & Head-Corporate Development |
|
Caroline D. Dorsa
Chairman |
|
Christopher A. Viehbacher
President, Chief Executive Officer & Director |
|
Daniel Quirk
Chief Medical Officer & Head-Medical Affairs |
|
Eric K. Rowinsky
Independent Director |
|
Ginger Gregory
Chief Human Resources Officer & Executive VP |
|
Jake Elkins
Vice President & Head-Acute Neurology Research |
|
Jane Grogan
Executive Vice President & Head-Research |
|
Jesus B. Mantas
Independent Director |
|
Lloyd B. Minor
Independent Director |
|
Maria C. Freire
Independent Director |
|
Menelas Nicolas Pangalos
Independent Director |
|
Michael E. Dambach
Treasurer & Vice President |
|
Monish Patolawala
Independent Director |
|
Nancy A. Simonian
Vice President-Medical Research & Development |
|
Nicole Murphy
Head-Pharmaceutical Operations & Technology |
|
Priya Singhal
Head-Development |
|
Rachid Izzar
Head-Global Product Strategy & Commercialization |
|
Richard Charles Mulligan
Director |
|
Robert Kilo
Account Director |
|
Robin C. Kramer
Chief Financial Officer |
|
Sean Godbout
Chief Accounting Officer, VP & Global Controller |
|
Stephen A. Sherwin
Independent Director |
|
Susan H. Alexander
Chief Legal Officer & Executive Vice President |
|
Susan Langer
Independent Director |
|
Timothy Power
Head-Investor Relations |
|
Wendell C. Taylor
Secretary & Chief Counsel |
|
William A. Hawkins
Independent Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.